From Ann Moriarty and colleagues: The College of American Pathologists' First 3 Years' Experience With High-Risk Human Papillomavirus Proficiency Testing for Cytology and Other Laboratories

http://dx.doi.org/10.5858/arpa.2012-0149-CP

Article Citation:

Ann T. Moriarty, Joel S. Bentz, Barbara Winkler, Andrew H. Fischer, Rodolfo Laucirica, Rhona J. Souers, Nicole Thomas, and Chengquan Zhao (2013) The College of American Pathologists' First 3 Years' Experience With High-Risk Human Papillomavirus Proficiency Testing for Cytology and Other Laboratories. Archives of Pathology & Laboratory Medicine: May 2013, Vol. 137, No. 5, pp. 606-609.

CAP LABORATORY IMPROVEMENT PROGRAMS

The College of American Pathologists' First 3 Years' Experience With High-Risk Human Papillomavirus Proficiency Testing for Cytology and Other Laboratories

Ann T. Moriarty , MD; Joel S. Bentz , MD; Barbara Winkler , MD; Andrew H. Fischer , MD; Rodolfo Laucirica , MD; Rhona J. Souers ,MS; Nicole Thomas , MPH, CT(ASCT); Chengquan Zhao , MD

From the Department of Esoteric Testing, AmeriPath Indiana, Indianapolis (Dr Moriarty); the Pathology Department, Laboratory Medicine Consultants, Las Vegas, Nevada (Dr Bentz); the Pathology Department, Mt Kisco Medical Group, Mt Kisco, New York (Dr Winkler); the Department of Pathology, University of Massachusetts Memorial Health Care, Worcester (Dr Fischer); Anatomic Pathology, Baylor College of Medicine, Houston, Texas (Dr Laucirica); Biostatistics (Ms Souers) and Survey (Ms Thomas), College of American Pathologists, Northfield, Illinois; and the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Zhao).

Context.—The College of American Pathologists (CAP) Human Papillomavirus (High-Risk) Survey for Cytopathology and Other Laboratories (CHPV) meets the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) requirements for 5 proficiency testing challenges analyzed 3 times per year. This study reports laboratory performance for CHPV from 2008 through 2010.

Objective.—To identify trends in proficiency testing performance for subscribers to the CAP CHPV.

Design.—CHPV responses were evaluated by using a nonlinear mixed model (significance level of .05) with a 2-factor interaction term and repeated measures component, comparing year, media, method, and intended response. Media types included Digene transport, SurePath, ThinPrep media, or a mixture of media types. Proficiency testing challenges validated at 80% consensus.

Results.—All challenges validated; 476 laboratories submitted 14 911 responses with 14 620 correct responses (98%). There were no differences between positive or negative challenges, or rate of correct responses; significant differences existed between media types by year and methods. Digene and ThinPrep media performed better than SurePath (P < .001;P = .03). There was a statistically significant difference between methods (P < .001); “other commercial kits,” “other (noncommercial)” tests, and Third Wave performed more poorly than others.

Conclusions.—Laboratories performed well when testing for human papillomavirus in CHPV during a period of 3 years. All challenges performed to the 80% threshold. Significant differences were found between methods and media. The CAP CHPV survey provides useful information for laboratories choosing human papillomavirus testing methods.